A
Aparna Raj Parikh
Researcher at Harvard University
Publications - 151
Citations - 3483
Aparna Raj Parikh is an academic researcher from Harvard University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 17, co-authored 101 publications receiving 1554 citations. Previous affiliations of Aparna Raj Parikh include University of North Carolina at Chapel Hill & City of Hope National Medical Center.
Papers
More filters
Journal ArticleDOI
Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
Al B. Benson,Alan P. Venook,Mahmoud M. Al-Hawary,Mustafa A. Arain,Yi Jen Chen,Kristen K. Ciombor,Stacey Cohen,Harry S. Cooper,Dustin A. Deming,Linda Farkas,Ignacio Garrido-Laguna,Jean L. Grem,Andrew J. Gunn,J. Randolph Hecht,Sarah E. Hoffe,Joleen M. Hubbard,Steven C. Hunt,Kimberly L. Johung,Natalie Kirilcuk,Smitha S. Krishnamurthi,Wells A. Messersmith,Jeffrey A. Meyerhardt,Eric D. Miller,Mary F. Mulcahy,Steven J. Nurkin,Michael J. Overman,Aparna Raj Parikh,Hitendra Patel,Katrina S. Pedersen,Leonard B. Saltz,Charles Schneider,David Shibata,John M. Skibber,Constantinos T. Sofocleous,Elena M. Stoffel,Eden Stotsky-Himelfarb,Christopher G. Willett,Kristina M. Gregory,Lisa A. Gurski +38 more
TL;DR: The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Colon Cancer focuses on systemic therapy options for the treatment of metastatic colorectal cancer (mCRC), because important updates have recently been made to this section as discussed by the authors.
Journal ArticleDOI
Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical Trial.
Janet E. Murphy,Jennifer Y. Wo,David P. Ryan,Jeffrey W. Clark,Wenqing Jiang,Beow Y. Yeap,Lorraine C. Drapek,Leilana Ly,Christian V. Baglini,Lawrence S. Blaszkowsky,Cristina R. Ferrone,Aparna Raj Parikh,Colin D. Weekes,Ryan D. Nipp,Eunice L. Kwak,Jill N. Allen,Ryan B. Corcoran,David T. Ting,Jason E. Faris,Andrew X. Zhu,Lipika Goyal,David H. Berger,Motaz Qadan,Keith D. Lillemoe,Nilesh Talele,Rakesh K. Jain,Thomas F. DeLaney,Dan G. Duda,Yves Boucher,Carlos Fernandez-del Castillo,Theodore S. Hong +30 more
TL;DR: Total neoadjuvant therapy with FOLFIRINOX, losartan, and chemoradiotherapy provides downstaging of locally advanced pancreatic ductal adenocarcinoma and is associated with an R0 resection rate of 61%.
Journal ArticleDOI
Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers.
Aparna Raj Parikh,Ignaty Leshchiner,Liudmila Elagina,Lipika Goyal,Chaya Levovitz,Giulia Siravegna,Dimitri Livitz,Kahn Rhrissorrakrai,Elizabeth E. Martin,Emily E. Van Seventer,Megan Hanna,Kara Slowik,Filippo Utro,Christopher J. Pinto,Alicia Wong,Brian P. Danysh,Ferran Fece de la Cruz,Isobel J Fetter,Brandon Nadres,Heather A. Shahzade,Jill N. Allen,Lawrence S. Blaszkowsky,Jeffrey W. Clark,Bruce J. Giantonio,Janet E. Murphy,Ryan D. Nipp,Eric Roeland,David P. Ryan,Colin D. Weekes,Eunice L. Kwak,Jason E. Faris,Jennifer Y. Wo,François Aguet,Ipsita Dey-Guha,Mehlika Hazar-Rethinam,Dora Dias-Santagata,David T. Ting,Andrew X. Zhu,Theodore S. Hong,Todd R. Golub,Todd R. Golub,Todd R. Golub,A. John Iafrate,Viktor A. Adalsteinsson,Alberto Bardelli,Laxmi Parida,Dejan Juric,Gad Getz,Ryan B. Corcoran +48 more
TL;DR: Direct prospective comparison of circulating tumor DNA and tissue biopsy sequencing shows the superiority of liquid biopsies for capturing clinically relevant alterations mediating resistance to targeted therapies in cancer patients.
Journal ArticleDOI
Rectal cancer, version 6.2020: Featured updates to the NCCN guidelines
Al B. Benson,Al B. Benson,Alan P. Venook,Alan P. Venook,Mahmoud M. Al-Hawary,Mahmoud M. Al-Hawary,Mustafa A. Arain,Mustafa A. Arain,Yi Jen Chen,Yi Jen Chen,Kristen K. Ciombor,Kristen K. Ciombor,Stacey Cohen,Stacey Cohen,Harry S. Cooper,Harry S. Cooper,Dustin A. Deming,Dustin A. Deming,Ignacio Garrido-Laguna,Ignacio Garrido-Laguna,Jean L. Grem,Jean L. Grem,Andrew Gunn,Sarah E. Hoffe,Sarah E. Hoffe,Joleen M. Hubbard,Joleen M. Hubbard,Steven C. Hunt,Steven C. Hunt,Natalie Kirilcuk,Natalie Kirilcuk,Smitha S. Krishnamurthi,Smitha S. Krishnamurthi,Wells A. Messersmith,Wells A. Messersmith,Jeffrey A. Meyerhardt,Jeffrey A. Meyerhardt,Eric D. Miller,Eric D. Miller,Mary F. Mulcahy,Mary F. Mulcahy,Steven J. Nurkin,Steven J. Nurkin,Michael J. Overman,Michael J. Overman,Aparna Raj Parikh,Aparna Raj Parikh,Hitendra Patel,Hitendra Patel,Katrina S. Pedersen,Katrina S. Pedersen,Leonard Saltz,Leonard Saltz,Charles Schneider,Charles Schneider,David Shibata,David Shibata,John M. Skibber,John M. Skibber,Constantinos T. Sofocleous,Constantinos T. Sofocleous,Elena M. Stoffel,Elena M. Stoffel,Eden Stotsky-Himelfarb,Eden Stotsky-Himelfarb,Christopher G. Willett,Christopher G. Willett,Alyse Johnson-Chilla,Alyse Johnson-Chilla,Lisa A. Gurski,Lisa A. Gurski +70 more
TL;DR: These NCCN Guidelines Insights summarize the panel discussion behind recent important updates to the guidelines, clarifying the definition of rectum and differentiating the rectum from the sigmoid colon; the total neoadjuvant therapy approach for localized rectal cancer; and biomarker-targeted therapy for metastatic colorectal cancer.
Journal ArticleDOI
Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX.
Theodoros Michelakos,Ilaria Pergolini,Carlos Fernandez-del Castillo,Kim C. Honselmann,Lei Cai,Vikram Deshpande,Jennifer Y. Wo,David P. Ryan,Jill N. Allen,Lawrence S. Blaszkowsky,Jeffrey W. Clark,Janet E. Murphy,Ryan D. Nipp,Aparna Raj Parikh,Motaz Qadan,Andrew L. Warshaw,Theodore S. Hong,Keith D. Lillemoe,Cristina R. Ferrone +18 more
TL;DR: Whether preoperative factors can predict resectability of borderline resectable and locally advanced pancreatic ductal adenocarcinoma after neoadjuvant FOLFIRINOX and which patients might benefit from adjuvant therapy is investigated.